Mutations of the TP53 tumor suppressor gene have been associated with poor survival in some series of diffuse large B-cell lymphoma (DLBCL), but not in other studies. The purpose of this study was to identify the frequency of TP53 alterations (mutations or deletions), characterize the gene expression of mutant/deleted cases, and determine the effects of mutations on survival. In a series of DLBCL that had previous gene expression profiling, we identified 24 mutations in 113 cases (21%). There was no difference in the frequency of mutations in the molecular subgroups of DLBCL. Twelve of the 24 cases (50%) had mutations localized to the DNA binding codons in the core domain of TP53. The presence of any TP53 mutation correlated with poor overall survival (OS; P = 0.044), but DNA-binding mutations were the most significant predictor of poor OS (P < 0.001). Multivariate analysis confirmed that the International Prognostic Index, tumor size, and TP53 DNA binding mutations were independent predictors of OS. Gene expression analysis showed that TRAIL receptor-2 (DR5) was the most differentially underexpressed gene in the TP53 mutated cases. Investigation is warranted into targeted therapy towards TRAIL receptor-2, to potentially bypass the adverse effect of mutated TP53 in DLBCL.
INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin's lymphoma and comprises 35-40% of adult lymphomas 1,2 . This disease represents a clinically and genetically heterogeneous entity, and develops either de novo, or as a high-grade transformation from low-grade B-cell lymphoma. In the pre-rituximab era, DLBCL treated with conventional chemotherapy, with or without radiotherapy, demonstrated progression free survival of approximately 70% in early stage and 50% in advanced stage disease. However, due to disease progression, about half of all patients exhibit poor overall survival. Overall survival has been significantly improved in DLBCL by the addition of rituximab [3] [4] [5] [6] .
The International Prognostic Index (IPI) has been widely used to predict the prognosis in DLBCL 7, 8 . However, the molecular events that are important in explaining the IPI values are only partially known 9 . In our recent studies using a complimentary DNA (cDNA) Lymphochip microarray, three distinct molecular subgroups of DLBCL were identified, including germinal center B-cell-like (GCB), activated B cell-like (ABC), and primary mediastinal B-cell (PMBL), leaving a heterogeneous group of cases that are not classifiable [10] [11] [12] [13] . These results have shown that DLBCL patients with GCB and PMBL subtypes have a significantly better overall survival (OS) than those with the ABC or unclassifiable subtypes 10, 11, 13, 14 . Alternatively, DLBCL analyzed with Affymetrix oligonucleotide microarrays has been subclassified into oxidative phosphoylation, B-cell receptor/proliferation and host response molecular subgroups 15, 16 .
To better understand these differences in survival of various types of DLBCL, the TP53 tumor suppressor gene is of particular interest because it plays a critical role in the regulation of cell 24, 25 , and chronic lymphocytic leukemia [26] [27] [28] .
In DLBCL, however, the role of an altered TP53 gene in predicting survival remains controversial. Early studies found that TP53 mutations were associated with a low rate of complete remission and predicted for poor OS in the low or intermediate IPI risk groups of patients [29] [30] [31] . More recent studies have demonstrated that TP53 mutation or deletion predicts treatment resistance and short survival in the plasmablastic/plasmacytoid variant of DLBCL 32, 33 .
However, other studies failed to demonstrate that TP53 mutations correlated with prognosis 34, 35 .
In addition, no studies have reported the frequency of TP53 mutations in the molecular subgroups of DLBCL, or described the gene expression pattern of DLBCL with TP53 mutations.
We hypothesized that the frequency of TP53 alterations would be higher in the ABC subtype of DLBCL, and provide a partial basis for the poor OS observed in that subtype. We also hypothesized that DNA binding TP53 mutations may have the greatest impact on survival, as previously observed in solid tumors [36] [37] [38] . Therefore, to test these hypotheses and to clarify the previous conflicting observations, mutational analysis and fluorescence in situ hybridization (FISH) for TP53 were performed in a large series of DLBCL. Our goals were to determine: (1) the differences in clinical characteristics and survival between DLBCL with or without TP53 
METHODS

Patient information
These cases were derived from a series of 240 patients with DLBCL, that were previously profiled with the Lymphochip cDNA microarray by the Lymphoma/Leukemia Molecular Profiling Project (LLMPP) 11 . The de novo cases in the series represented newly diagnosed, untreated patients, including both nodal and extra-nodal cases, who received anthracycline containing regimens without rituximab. After power calculations, 113 cases were chosen for mutation analysis from DNA available on the 240 cases. Of the 240 cases, 132 cases had paraffin material available for deletion studies. The recently published Bayesian classification system was used to define the molecular profiles of the DLBCL cases 12 . Thirteen patients who did not receive a curative regimen and four patients with incomplete survival information were excluded from the analysis of clinical characteristics and survival. The Institutional Review
Board of the University of Nebraska Medical Center approved this study.
Mutational analysis of TP53 by denaturing high-performance liquid chromatography (DHPLC)
Genomic DNA was extracted simultaneously with RNA from the same frozen tissue samples.
Exons 5 -8 of the TP53 gene were amplified using previously published polymerase chain reaction (PCR) primer sequences 23 , 500 ng genomic DNA, 1.5 U Amplitaq polymerase, 100 mM 
RT-PCR analysis of TRAIL receptor-2
Total RNA was re-extracted from frozen tissue of three cases with TP53 DNA binding mutations and three wild-type cases with Lymphochip data. After homogenization of the tissue in Triazol -∆∆CT with GAPDH as a calibrator 42, 43 .
Survival analysis
The Kaplan-Meier method was used to estimate overall survival (OS) and event-free survival (EFS) of the patients. The log-rank test was used to compare the differences in clinical parameters, and the survival differences between subgroups with and without TP53 mutation/deletion. OS was defined as the time from diagnosis to death resulting from any cause or, for patients remaining alive, the time from diagnosis to last contact. EFS was defined as the time from diagnosis to the occurrence of the first relapse or death from any cause or, for patients remaining alive and relapse-free, the time from diagnosis to last contact. Fisher's exact test for 2 x 2 tables and the student t-test were used for analysis of the distributions of categorical data between groups. Multivariate analysis using the Cox Regression Model was used to evaluate which variables were potential independent prognostic factors for OS. SAS software was used for the data analysis (SAS Institute Inc., Cary, NC, USA).
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RESULTS
TP53 gene mutations
Of the 113 analyzed cases, 24 cases (21%) contained TP53 mutations including 22 single base missense mutations, one single base deletion (codon 152), and one 10 base insertion (codon 282) ( Table 1 ). The mutations included six in exon 5, five in exon 6, seven in exon 7 and six in exon 8. A known polymorphism at codon 213 was identified in one case. For the ABC subtype, mutations were found in 11 of 45 cases (24%), whereas 11 of 37 cases (30%) were mutated in the GCB subtype (P = 0.43). No mutations were seen in the seven PMBL cases, but mutations were identified in two of 24 unclassifiable cases (8%).
In six cases, mutations were localized in codons previously described as TP53 hot spots in NHL 30, 33, 44, 45 . When the mutation distribution pattern was analyzed on the TP53 molecule, 12 mutations (50%) were found in codons involved in DNA binding in the core domain. These 
TP53 gene deletions
Similar frequencies and distribution pattern were also noted for TP53 gene deletion (24% in ABC and 26% in GCB subtypes, respectively, P = 0.52) ( Table 2 ). The frequency of deletions was 14% and 9% in the PMBL and unclassifiable subtypes, respectively. However, since there are few cases in the PMBL subtype and the unclassifiable cases are heterogeneous, these subtypes will not be discussed in survival analysis of molecular subtypes. Alterations in TP53, which are defined as either mutation or chromosomal deletion occurred in 43 of 92 (47%) of cases.
mRNA expression pattern of TP53 mutant cases
Supervised analysis of Lymphochip expression data demonstrated that 135 genes were differentially expressed in the TP53 mutant cases (P< 0.001). Decreased expression with the greatest statistical difference was seen in TRAIL receptor-2 (DR5), followed by other TP53 target genes such as DDBP-2 (XRCC1), XPC, CDKN1A (p21) and BAX (Table 3) . TRAIL receptor-2 is also identified as the most differentially expressed gene, followed by TP53, BAX, and DDBP-2 in the DNA binding subset of TP53 mutations (Figure 1 ). The decreased expression of TRAIL receptor-2 was confirmed by RT-PCR analysis in a representative sample of three cases with DNA binding TP53 mutations compared to three wildtype cases (Table 4) . We found that it is possible to construct a 22 gene predictor that has an accuracy of 70% (range 60-80%) in identifying cases with TP53 mutations, depending on the analytical tool utilized. T-cell receptor and other T-cell surface antigens tend to be under expressed in TP53 mutant cases. In TP53 deleted cases, there was differential expression of 11 genes with the greatest decrease in expression for TP53 followed by IFIT3, TRAIL receptor-2, and the DVL2 gene, which is colocalized with TP53 on chromosome 17p13 (Table 5 ).
TP53 and CDKN1A (p21) mRNA expression
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From Significantly decreased TP53 mRNA was found in DLBCL with TP53 mutations (median = 0.62) or deletions (median = 0.58) compared to the corresponding wildtype cases for each assay (no mutation -median = 0.81, no deletion -median = 0.88), P< 0.001 (Table 6 ). The results of CDKN1A mRNA expression were similar to the TP53 results. The microarray data showed that DLBCL with TP53 mutations exhibited decreased CDKN1A mRNA expression (median = 0.53; P=0.001), as did DLBCL marginally with TP53 deletions (median = 0.55; P=0.058), when compared to DLBCL with wildtype TP53 (medians = 0.70 and 0.68, respectively, Table 6 ).
p53 and p21 protein expression
Expression of the p53 protein was found in 40 of 72 cases (56%). However, only 13 of the 40 protein positive cases (32%) had an altered TP53 gene. Expression of p53 was seen in 13 of 16 mutant cases (81%), but expression was also paradoxically seen in 27 of 56 cases (48%) with wildtype TP53 (Table 7) . Expression of p21 protein was found in 28 of 63 cases (44%), and most of these cases, 26 of the 28 (93%) had the WT TP53 gene ( 
Clinical characteristics
Supplemental Table 1 summarizes the major clinical characteristics of 92 DLBCL patients with both TP53 mutation and deletion data compared to cases with wild-type TP53. The two groups did not differ significantly in clinical characteristics (Supplemental Table 1 ). The median age at diagnosis overall was 62.6 years (range; 14.4-83 years). Sixty-two of 84 (73%) patients with data achieved a complete remission (CR), 11 (13%) had a partial response (PR), and 13 (14%) had no response after initial treatment. There was no significant difference in the proportion of patients who achieved a CR based on TP53 status (WT-81% versus mut-62%; P = 0.33). However, in contrast, the patients with TP53 mutations in the DNA binding codons exhibited a lower complete remission rate (45%) than those with WT TP53 (81%) (P = 0.049).
Supplemental Table 2 summarizes the clinical characteristics that were predictors of OS in the 90 cases of DLBCL with clinical data. Univariate analysis showed that the number of extranodal sites, serum LDH levels, performance status, clinical stage, B-symptoms, tumor size and IPI risk groups were significant predictors of OS in DLBCL. A significant difference in OS and EFS was noted in high-risk (3 -5) IPI group versus low (0 -2) IPI groups (P < 0.0001).
Survival analysis of DLBCL cases with TP53 alterations
Twenty-three of 24 patients with TP53 mutations had survival data available for analysis. While TP53 mutations predicted for poor OS (P = 0.044), there was no significant difference in survival between the deletion or combined alteration subgroups compared to the WT TP53 group (Figures 2A-2C) . TP53 mutations did not predict for poor survival in the ABC subtype ( Figure 2D ; P=0.96). While there was a suggestion of poor OS within the GCB subtype ( Figure 2E ; P= 0.057), it was not statistically significant. Since the presence of any TP53 mutation was mildly predictive for poor OS, we hypothesized that the distribution pattern of TP53 mutations in the core domain may be even more predictive. The 12 cases with TP53 mutations in DNA binding codons had a significantly worse median OS (0.74) years compared to the 11 cases with mutations in the non-DNA binding codons (2.59 years), or the patients with WT TP53 (5.4 years) (Figures 3A-3B ). No significant difference on EFS was found between WT and mutant TP53 groups ( Figure 4A ). However, cases with DNA binding domain mutations similarly had poor median EFS (0.54 years) ( Figure 4B ), compared to wildtype cases (2.97 years), but it was not statistically significant (p=0.053). This is most likely due to the fact that EFS data was available on 6 fewer patients (55), than was available for OS (61 patients). 
Specific p53+/p21-immunophenotype predicts for survival
Patients with the p53+/p21-phenotype had a significantly worse OS compared to with p53-or p53+/p21+ immunophenotypes (P = 0.023, Figure 5 ). However, multivariate analysis failed to confirm the p53
-phenotype as an independent prognostic factor (P > 0.05, data not shown).
DISCUSSION
In our study, the frequency of TP53 mutations (21%) in DLBCL is similar to that of the average frequency of 23% in previous reports in DLBCL 21, 29, 31, [48] [49] [50] . TP53 mutations occurred with similar frequencies in the ABC and GCB subtypes (24% versus 30%), indicating that TP53 No previous study has examined the gene expression profile of DLBCL with a mutant TP53. 28 . Our study also shows that p53 mRNA is decreased in TP53 mutated cases. Therefore, TRAIL receptor-2 may be decreased by two mechanisms, a lack of upregulation by mutant TP53 and a dosage effect by deletion of one allele in other cases.
In vitro studies have shown that the use of exogenous TRAIL or antibodies to TRAIL receptor-2 will stimulate the receptor with the regain of normal apoptosis in lymphoma cell lines with TP53 mutations [54] [55] [56] , including cell lines derived from DLBCL 54 . This is in contrast to chronic lymphocyte leukemia or mantle cell lymphoma where TRAIL receptor 1 (DR4) is activated, but TRAIL receptor-2 is not upregulated 57 . CP-31398 treatment of cell lines has been shown to upregulate TRAIL receptor-2 58 . Other investigators have shown that small molecules can increase TRAIL receptor-2 and CDKN1A(p21) in TP53 null colon cancer cell lines 59 . While
Georgakis et al attempted to determine which lymphoma patients might benefit from human agonistic antibodies to TRAIL death receptors, they did not examine the TP53 mutation status 56 .
In summary, our findings suggest that upregulation of TRAIL receptor-2 may potentially be useful to investigate for therapy to bypass the mutated TP53 pathway in DLBCL.
Similar to our previous observation of decreased expression of genes colocalized on 17p13 in mantle cell lymphoma with deletion of 17p13 39 
, whereas only 2 of 11 patients (18%) with a TP53 mutation located outside these regions died (P < 0.01). Five of 12 patients carrying mutations in the DNA binding domain exhibited disease progression with partial or no response to CHOP-based chemotherapy, whereas only one of 11 patients with a TP53 mutation located in other codons showed disease progression.
Mutations that cause structural defects in TP53 seem to contribute to a more aggressive biological behavior. and Arg 283 interacts to bind with the DNA major groove 46 . The majority of the mutations in these regions will result in loss of DNA binding capacity. The results of this study support the conclusion that the location of TP53 mutations in exons 5-8 plays a pivotal role in determining the biological behavior of DLBCL. Recent studies have also indicated that TP53 mutations continue to be predictive of poor OS with Rituxan-CHOP therapy 65 .
In conclusion, this report demonstrates two new findings. First, the DNA binding mutations in the core domain of TP53 are significantly associated with poor overall survival in DLBCL.
Secondly, TRAIL receptor-2 may be a potential target to investigate for therapeutic intervention in DLBCL patients with p53 mutations.
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